In surgeries requiring anticoagulation, especially cardiac and major vascular procedures, agents like protamine sulfate are used to counteract the effects of unfractionated heparin. Protamine works by forming a stable complex with heparin, neutralizing its anticoagulant properties and reducing the risk of postoperative bleeding. The usual dose is about 1 mg of protamine per 100 units of circulating heparin, given slowly, because rapid injection causes hypotension and pulmonary hypertension; severe reactions are more likely in patients previously exposed to protamine-containing insulin, with fish allergy, or after vasectomy. Heparin rebound can follow hours later as tissue-bound heparin re-enters the circulation. Research is ongoing into other heparin-neutralizing agents like platelet factor 4 (PF4), though they are not yet widely used.
For newer oral anticoagulants like rivaroxaban and apixaban, andexanet alfa, a recombinant Factor Xa decoy protein, has been developed to reverse their effects in cases of severe bleeding or emergency surgery. Idarucizumab reverses dabigatran, and four-factor prothrombin complex concentrate with vitamin K reverses warfarin and is the usual fallback when andexanet alfa is unavailable. These agents are a significant advancement in critical care, where rapid reversal of anticoagulation can be life-saving in trauma or urgent surgeries.
| Agent | Reverses | Key points |
|---|---|---|
| Naloxone | Opioid-induced respiratory depression (for the newborn, ventilation rather than naloxone is first-line) | Binds mu-opioid receptors and displaces opioids; onset 1-2 minutes IV; titrate 40 mcg at a time postoperatively; lasts 30-60 minutes, so watch for renarcotization; abrupt reversal causes withdrawal with tachycardia, nausea and vomiting |
| Flumazenil | Benzodiazepine over-sedation, prolonged recovery or overdose | Competitive antagonist at GABAA receptors; shorter half-life than some benzodiazepines, so repeat dosing or infusion may be needed. Titrate 0.2 mg at a time; use cautiously with chronic benzodiazepine use, seizure disorders, or tricyclic co-ingestion |
| Intralipid | Local anesthetic systemic toxicity from agents such as bupivacaine or lidocaine | Lipid sink plus direct cardiac effects; 1.5 mL/kg bolus of 20% emulsion then 0.25 mL/kg/min, bolus repeatable, ceiling about 12 mL/kg |
| Atipamezole | Dexmedetomidine and other alpha-2 agonist sedation | Alpha-2 antagonist; still largely experimental and not yet common in clinical practice |
| Protamine sulfate | Unfractionated heparin | Forms a stable complex with heparin; about 1 mg per 100 units of heparin, given slowly (hypotension and anaphylactoid reactions possible); watch for heparin rebound |
| Platelet factor 4 | Heparin (under investigation) | Research ongoing; not yet widely used |
| Andexanet alfa | Rivaroxaban and apixaban in severe bleeding or emergency surgery | Recombinant Factor Xa decoy protein; idarucizumab reverses dabigatran and four-factor PCC with vitamin K reverses warfarin |
